2017
DOI: 10.7196/sarj.2017.v23i1.154
|View full text |Cite
|
Sign up to set email alerts
|

Outcomes of resectable pulmonary aspergilloma and the performance gap in a high tuberculosis prevalence setting: A retrospective study

Abstract: Background. Pulmonary aspergillomas develop in patients with underlying structural lung diseases. The mainstay of therapy is surgery. Objectives. To assess treatment and clinical outcomes following diagnosis of potentially resectable pulmonary aspergilloma at the Tygerberg Hospital (TBH) between January 2013 and December 2015.Methods. This was a retrospective analysis conducted at TBH. Patients were followed up between 6 and 29 months following diagnosis to analyse outcomes. Results. Fifty-nine patients presen… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2021
2021
2023
2023

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(2 citation statements)
references
References 28 publications
(41 reference statements)
0
2
0
Order By: Relevance
“…[1] Moreover, in under-resourced, overburdened centres there may be a considerable delay between presentation and surgery, and patients with severe post-TB lung disease or other comorbidities may not be candidates for surgical intervention. [7] Several endovascular techniques have been reported for the treatment of PA aneurysms other than Rasmussen's, among these, the Amplatzer vascular plug (AVP; Abbott Laboratories, USA), shown in Fig. 1.…”
Section: In Practicementioning
confidence: 99%
“…[1] Moreover, in under-resourced, overburdened centres there may be a considerable delay between presentation and surgery, and patients with severe post-TB lung disease or other comorbidities may not be candidates for surgical intervention. [7] Several endovascular techniques have been reported for the treatment of PA aneurysms other than Rasmussen's, among these, the Amplatzer vascular plug (AVP; Abbott Laboratories, USA), shown in Fig. 1.…”
Section: In Practicementioning
confidence: 99%
“…(Table 1). Seventeen (41.5%) studies were retrospective chart reviews [12][13][14][15][16][17][18][19][20][21][22][23][24][25][26][27][28], 12 (29.3%) were case reports [29][30][31][32][33][34][35][36][37][38][39][40], 5 case series (12.2%) [8,[41][42][43][44], 5 prospective cohorts [45][46][47][48][49], and 2 cross-sectional studies [50,51]. The majority of the studies were from East (n = 11) and West (n = 10) Africa.…”
Section: Summary Of Studiesmentioning
confidence: 99%